9 August 2012
Scientists have developed a new prostate cancer screening method which combines a new drug therapy and gradual changes in prostate specific antigen (PSA) levels to identify individuals who are more likely to have an aggressive form of the disease despite biopsies coming back negative.
According to the paper, published in the Journal of Urology, PSA can be a much more effective market for prostate cancer when a drug therapy is used in conjunction with it. Currently most physicians use it as a standalone test.
Lead investigator Dr Steven A Kaplan explained that the value of PSA is being "increasingly debated," and the research showed that when it is used in a specific way, PSA can be especially useful identifying males with prostate cancer than was previously undetected.
He said: "We have shown that using PSA with these drugs can help us differentiate prostate cancer from benign prostate disease in patients who are difficult to diagnose."
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.